Evgen Pharma PLC Grant of share options, issue of equity and TVR (1353U)
10 July 2018 - 8:00PM
UK Regulatory
TIDMEVG
RNS Number : 1353U
Evgen Pharma PLC
10 July 2018
10 July 2018
Evgen Pharma plc
("Evgen" or "the Company")
Grant of share options, issue of equity and total voting
rights
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer and neurological conditions
announces that Sally Ross, the Company's Clinical Development
Officer, has been granted nil cost options over a total of 368,304
ordinary shares in the Company. The options are exercisable,
subject to the option vesting, for a period of up to ten years from
the date of grant under the Evgen Pharma plc Long Term Incentive
Plan ("LTIP").
The number of nil cost options awarded has been calculated by
reference to the three month average share price to 3 July 2018.
These nil cost options are subject to the rules of the LTIP and
will vest based on share price performance between the date of
grant and the third anniversary of grant.
Issue of Equity
In addition, the Company announces that it has received a notice
to exercise options over 80,000 ordinary shares in the Company. The
options were granted under an individual option agreement and have
an exercise price of 7.3 pence per share. Accordingly, the Company
has issued and allotted 80,000 new ordinary shares of 0.25 pence
each ("New Ordinary Shares"). The New Ordinary Shares rank pari
passu with the Company's existing issued ordinary shares.
Application has been made to admit the New Ordinary Shares to
trading on AIM and dealings in these shares are expected to
commence at 8.00 a.m. on 12 July 2018.
Total Voting Rights
There are no shares held in treasury, therefore following the
admission of the New Ordinary Shares the total number of voting
rights in the Company will be 93,356,858. This figure may be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest under the
Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc
Dr Stephen Franklin, CEO +44 (0) 01625
Richard Moulson, CFO 466591
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price (Corporate
Finance)
John Howes, Rob Rees (Corporate +44 (0) 20
Broking) 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
Details of the person discharging managerial responsibilities/person closely associated
----------------------------------------------------------------------------------------------------------------------
Name Sally Ross
------------------------------------------------------------------ --------------------------------------------------
Reason for the notification
----------------------------------------------------------------------------------------------------------------------
Position/status Clinical Development Officer
------------------------------------------------------------------ --------------------------------------------------
Initial notification /Amendment Initial Notification
------------------------------------------------------------------ --------------------------------------------------
Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------------
Name Evgen Pharma Plc
------------------------------------------------------------------ --------------------------------------------------
Legal Entity Identifier 213800NO3E6TSTQO8K20
------------------------------------------------------------------ --------------------------------------------------
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------------
Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each
GB00BSWYN304
Identification code
------------------------------------------------------------------ --------------------------------------------------
Nature of the transaction Grant of options
------------------------------------------------------------------ --------------------------------------------------
Currency GBP
------------------------------------------------------------------ --------------------------------------------------
Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------------------------------ ------------------------- -----------------------
nil 368,304
-------------------------------------------------------------------------------------------- -----------------------
Aggregated information
- Aggregated volume
- Price
- Aggregated total
--------------------------------------------------------------------------------------------- -----------------------
Date of the transaction 7 July 2018
------------------------------------------------------------------ --------------------------------------------------
Place of the transaction Off market
------------------------------------------------------------------ --------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFESASFASESW
(END) Dow Jones Newswires
July 10, 2018 06:00 ET (10:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024